FDA Approves New Dosage of Naloxone

The US Food and Drug Administration have announced their approval of a higher dose of naloxone hydrochloride nasal spray for the treatment of opioid overdose.

The drug is now approved in a dosage of 8 mg as well as the previously approved 2 mg and 4 mg dosages.

Use of naloxone in patients with opioid dependency can result in symptoms of opioid withdrawal, including body aches, diarrhea, tachycardia, fever, sneezing, piloerection, sweating, yawning, nausea, vomiting, nervousness, restlessness, irritability, shivering, abdominal cramps, and increased blood pressure.

—Michael Potts

Reference:

FDA approves higher dosage of naloxone nasal spray to treat opioid overdose. News release. US Food and Drug Administration; April 30, 2021. Accessed April 30, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-higher-dosage-naloxone-nasal-spray-treat-opioid-overdose